Isotope Labelling
Secure & rapid delivery of isotopically labelled (14C/SIL) materials for non-clinical & clinical human studies.
With over 30 years of successful delivery on-site, Quotient Sciences' highly trained chemists have extensive chemical and radiochemical knowledge and the experience required to supply consultancy and advice on the most suitable labelling positions for a variety of molecular entities.
Isotope Labelling Services Include:
•GMP & non GMP synthesis
•14C radiolabelling
•Ability to handle highly potent/high hazard compounds (cytotoxics)
•Synthesis of metabolites & reference standards aiding bioanalytical and metabolism studies
•Degradants and process impurities to support API development
•Route development and precursor synthesis for labelling with 3H and short-lived isotopes 11C and 18F
•Classical and non-classical synthetic techniques
•Flow chemistry
•Automated peptide synthesis capability
•Microbiological and bio-catalysis
•Stable isotope label (SIL) synthesis, including 2H, 13C, 15N & 18O
Isotope Labelling Resources
-
Info SheetIsotope LabellingWhether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.
-
Case StudiesStable Isotope Labelling Case StudyMultiple, biotechnology and large-pharma companies needing isotope labelling support for their ADME/hAME studies
-
Scientific PostersA Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers."A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers." The poster was presented at the Pharmacology 2022 conference and was co-authored with our customer, Galmed Pharmaceuticals
-
Scientific PostersBPS 2022 Poster - A Phase 1 Randomized PK Study of Amilo-5MERA Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers
Ready to get started?
Connect With Quotient Today